A meta-analysis of front-line therapy of osimertinib in treating non-small cell lung cancer

Abstract

Our meta-analysis was designed to explored the efficacy and safety of osimertinib as front-line strategy in advanced non-small-cell lung cancer (NSCLC) whose tumors had sensitive EGFR mutations. Computerized search for trials from CENTRAL, PubMed, Cochrane and EMBASE up to May, 2021. The investigated trials include investigated osimertinib in untreated NSCLC patients with EGFR-mutation. Our meta-analysis summarized the outcomes from 4 studies. Outcomes of this study revealed that PFS was significantly longer for patients treated with osimertinib than the standard EGFR-TKIs/placebo group. In terms of the PFS subgroup analyses, better PFS were found to be higher in patients treated with Osimertinib, regardless of the sex, EGFR-mutated status, and smoking history. Besides, osimertinib improved CNS efficacy in untreated NSCLC patients with EGFR-mutation. In terms of the treatment-related AE subgroup analyses, no difference was identified when comparing Osimertinib vs. the comparable group (p > 0.05). The results suggested that First-line osimertinib treatment achieved a clinically meaningful PFS benefit and tolerable AEs for treatment of advanced NSCLC patients with EGFR-mutated than the prior EGFR-TKI/placebo. Meanwhile, osimertinib seemed to be a better option for advanced patients with CNS metastases. In terms of efficacy and tolerability, osimertinib seemed to be a more appropriate upfront therapy among EGFR-mutant NSCLC.